HONG KONG – Chinese integrated health care group Golden Meditech Holding Ltd. has partnered up with Hong Kong Baptist University (HKBU)'s biology department to conduct research in the area of cell therapy with an aim to treat neurodegenerative diseases with stem cells.
HONG KONG – Shanghai Miracogen Inc., a Chinese startup focused on developing antibody-drug conjugates (ADCs) against cancer, introduced technologies from Dutch firm Synaffix BV to co-develop a potential best-in-class ADC product. Under the licensing agreement, valued up to $125 million, Miracogen will obtain nonexclusive rights to Synaffix's Glycoconnect and Hydraspace ADC technologies for use on its next clinical candidate.
HONG KONG – A newly set up Japanese biotech is continuing the development of a potential first-in-class drug for the treatment of neuropathic pain associated with genetic mutations. The Kyoto-based firm, Alphanavi Pharma Co. Ltd., is a carve-out business venture from Sumitomo Dainippon Pharma Co. Ltd.
HONG KONG – Commercial-stage biotech company Beigene Ltd. and clinical-stage company Bioatla LLC agreed to co-develop and bring to the market BA-3071, an investigational conditionally active biologic (CAB) CTLA4 antibody, as a monotherapy and in combination with Beigene's investigational anti-PD-1 antibody, tislelizumab, to treat cancer.
HONG KONG – Shanghai Miracogen Inc., a Chinese startup focused on developing antibody-drug conjugates (ADCs) against cancer, introduced technologies from Dutch firm Synaffix BV to co-develop a potential best-in-class ADC product. Under the licensing agreement, valued up to $125 million, Miracogen will obtain nonexclusive rights to Synaffix's Glycoconnect and Hydraspace ADC technologies for use on its next clinical candidate.
HONG KONG – A newly set up Japanese biotech is continuing the development of a potential first-in-class drug for the treatment of neuropathic pain associated with genetic mutations. The Kyoto-based firm, Alphanavi Pharma Co. Ltd., is a carve-out business venture from Sumitomo Dainippon Pharma Co. Ltd.
HONG KONG – Commercial-stage biotech company Beigene Ltd. and clinical-stage company Bioatla LLC agreed to co-develop and bring to the market BA-3071, an investigational CAB CTLA4 antibody, as a monotherapy and in combination with Beigene's investigational anti-PD-1 antibody, tislelizumab, to treat cancer.
HONG KONG – Asian drugmakers are increasingly embracing artificial intelligence (AI) technologies for drug discovery. The latest example is Japanese drug developer Ono Pharmaceutical Co. Ltd., which recently entered a partnership with U.S. AI-focused biotech firm Twoxar Inc.
HONG KONG – The biotech sector in greater China ended the financial year on a high note. Companies on the Hong Kong Stock Exchange reported better-than-expected results, including seven pre-revenue startups that went public over the last year, adding to the energy in the biotech space.
